Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. entered an underwriting agreement for a public offering of equity securities. The company is issuing 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants to purchase up to 4,931,506 shares of common stock at $18.2499 per warrant, with a $0.0001 exercise price per share. Underwriters also have a 30-day option to buy up to 1,643,835 additional shares.
The company expects net proceeds of about $187.6 million, or $215.8 million if the underwriters fully exercise the option, and plans to use them for working capital, including research, clinical development, and commercialization efforts such as advancing bempikibart into future clinical trials. Pre-funded warrants are immediately exercisable, subject to an Ownership Limit of 4.99% or 9.99%, adjustable up to 19.99% with 61 days’ notice, and will not be listed on an exchange.
Q32 Bio Inc. is conducting a primary offering of 6,027,399 shares of common stock and pre-funded warrants to purchase up to 4,931,506 shares at $18.25 per share (or $18.2499 per warrant), for total public offering proceeds of $199,999,523.0994 and estimated net proceeds of about $187.59 million.
Shares outstanding will be 29,708,814 after the transaction, or 31,352,649 if the underwriters’ option for 1,643,835 additional shares is exercised in full, excluding any warrant exercises; this is a baseline figure, not the amount being offered. New investors incur immediate dilution of about $8.13 per share relative to the as adjusted net tangible book value of $10.12.
The company plans to use the cash, together with existing funds, for working capital, including research, clinical development and commercialization, particularly advancing its alopecia areata candidate bempikibart into future trials. Q32 Bio highlights favorable 36‑week safety and pharmacokinetic data from the SIGNAL‑AA Part B study and notes repayment of approximately $6.8 million to terminate its loan with Silicon Valley Bank, while emphasizing that its stock and the non‑listed pre‑funded warrants can be volatile and illiquid and that investing involves significant risks.
Q32 Bio Inc. is conducting a primary offering of up to $200,000,000 of common stock and pre-funded warrants under an effective shelf registration, with underwriters holding a 30-day option to buy up to an additional $30,000,000 of common stock. The transaction also covers shares issuable upon exercise of the pre-funded warrants, which are exercisable immediately at $0.0001 per share, subject to ownership caps, and are not expected to trade on an exchange.
The company is a clinical-stage biotechnology firm focused on bempikibart (ADX-914) for alopecia areata and other autoimmune diseases. Part B of the Phase 2a SIGNAL-AA trial in 33 severe patients used a 36-week subcutaneous dosing regimen and showed a generally well-tolerated safety profile without treatment-related serious adverse events, while an open-label extension from Part A indicated durable hair growth supporting maintenance dosing. Management plans to advance bempikibart into a registration-directed program in the first half of 2027.
Q32 Bio previously reoriented its strategy around bempikibart, including a 2025 asset sale of ADX-097 to Akebia Therapeutics while retaining earlier-stage complement assets. As of March 31, 2026, net tangible book value was $46.3 million, or $3.17 per share, with 14,629,463 shares outstanding before subsequent PIPE and at-the-market issuances. On June 24, 2026, the company repaid approximately $6.8 million, terminating its loan with Silicon Valley Bank.
Q32 Bio Inc. reported 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart (ADX-914) in severe and very severe alopecia areata. In the modified intent-to-treat population of 25 patients, the mean Severity of Alopecia Tool (SALT) score was reduced by 35.3%, with a 37.8% reduction in severe patients and 27.4% in very severe patients.
Clinically meaningful responses were observed, with 40.0% of the mITT population and 30.3% of the full ITT population (33 patients) achieving SALT-20 at Week 36. Example cases showed patients reaching SALT-10 or SALT-0 and maintaining or deepening responses during 12–16 weeks off drug and into an open-label extension.
The company stated that bempikibart demonstrated a generally well-tolerated safety profile, with no Grade 3 or higher adverse events and low, mild injection site reaction rates among 33 treated patients. Pharmacokinetic data indicated steady state concentrations were achieved about 10 weeks earlier than in Part A, with negligible anti-drug antibodies. Q32 Bio plans to use the SIGNAL-AA data to engage the FDA on a registration-directed program targeting initiation in the first half of 2027.
Q32 Bio Inc. reported 36-week topline results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe and very severe alopecia areata. In 33 treated patients, the prespecified modified intent-to-treat analysis showed a 35.3% mean reduction in SALT score from baseline, with 40.0% of patients achieving a SALT-20 response at Week 36 in the mITT set and 30.3% in the ITT set of all enrolled patients.
Bempikibart was observed to have a generally well-tolerated safety profile, with no treatment-related serious adverse events or Grade 3 or higher events and mild injection site reactions in 36.3% of patients, corresponding to a 4% incidence across all dose administrations. Pharmacokinetic, pharmacodynamic and anti-drug antibody data were favorable, with the loading regimen achieving steady-state about 10 weeks earlier than in Part A and negligible ADA formation.
The Part A open-label extension in eight patients also supported longer-term tolerability and suggested durable or further hair growth for those maintaining hair at entry, reinforcing the importance of maintenance dosing. The company plans to advance bempikibart into a registration-directed program in the first half of 2027 and recently repaid the remaining approximately $6.8 million outstanding under its loan agreement with Silicon Valley Bank, which has now been terminated.
Q32 Bio Inc. has a large shareholder group led by Boxer Capital Management, LLC, Boxer Holdings, LP, Boxer Holdings GP, LLC, and Aaron Davis collectively reporting beneficial ownership of 3,149,310 shares of common stock as of June 30, 2026. This represents 13.30% of Q32 Bio’s outstanding common stock. The ownership is reported with shared voting and dispositive power over all 3,149,310 shares and no sole voting or dispositive power.
The percentage is calculated based on 23,681,415 shares outstanding, consisting of 16,956,415 shares outstanding as of May 1, 2026 plus 6,725,000 shares issued in a private placement that closed on May 28, 2026.
Q32 Bio Inc. Schedule 13G/A shows that a group of Carlyle-related entities reports shared beneficial ownership of 691,735 shares of Common Stock, representing 4.1% of the class as of June 18, 2026. The filing cites 16,956,415 shares outstanding as disclosed in the issuer's Form 10-Q filed May 5, 2026. The reporting chain traces record ownership to Abingworth Bioventures VII LP with investment/dispositive authority delegated to Abingworth LLP; multiple Carlyle entities disclaim direct beneficial ownership while the cover pages report shared voting and dispositive power.
Q32 Bio Inc. director Isaac Manke exercised stock options to acquire 53,521 shares of Common Stock on June 30, 2026 at an effective exercise price of $2.80 per share. Following the exercise, he directly holds 53,521 common shares and the corresponding option position reported in this filing has been fully exercised.
The exercised option, described as a Stock Option (Right to Buy), had granted rights over 53,521 shares of Common Stock and was fully vested and exercisable. After this transaction, the derivative position shown in the filing has a reported balance of 0 options, indicating a complete exercise of this award with no sale reported in this filing.
Q32 Bio Inc. filed a shelf registration to offer up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time, in one or more offerings. The prospectus states offerings will be made at prices and on terms determined at or prior to each offering and that specific terms will appear in prospectus supplements.
The prospectus notes the company completed a $55 million securities purchase on May 26, 2026 with related registration rights and discloses 1,025,654 pre-funded warrants exercisable at $0.0001 per share. The filing is a shelf registration (Form S-3) enabling future capital raises under Rule 415.